NCT06533657 - Unique Treatment of Oncology Pain in Advanced Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 12, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

Cancer Pain

Interventions

DRUG

Trichomylin® capsule (5 mg delta-9-tetrahydrocannabinol: 5 mg cannabidiol: 5 mg cannabichromene)

Cancer patients meeting eligibility criteria will receive Trichomylin® and self-titrate to effective dose.

Trial Locations (3)

RECRUITING

CancerCare Manitoba, Winnipeg

RECRUITING

Centre hospitalier de l'Université de Montréal, Montreal

RECRUITING

The Research Institute of the McGill University Health Centre, Montreal

All Listed Sponsors

lead

ZYUS Life Sciences Inc.

INDUSTRY